Eclipse Treatment Planning System
FDA Clearance Information
The Eclipse treatment planning system was cleared by the FDA via the 510(k) pathway on September 25, 2013. It is manufactured by Varian Medical Systems and is classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- For use by qualified medical professionals to calculate and plan radiation therapy treatments.
- Supports treatment planning for radiation therapy modalities and treatment techniques described in the cleared labeling.
- Used to model radiation dose distributions to help plan delivery of therapeutic radiation.
Clinical Applications
- Planning external-beam radiation therapy for patients with cancer.
- Calculating dose distributions for treatment plans.
- Evaluating target coverage and radiation dose to surrounding normal tissues.
- Supporting treatment planning for sites such as the brain and other anatomic regions treated with external-beam radiation.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- Eclipse is software, not an implantable or disposable device, so it does not have a physical device size or vessel compatibility profile.
- Treatment plans require review and approval by qualified radiation oncology professionals before delivery.
- Dose calculations and plan quality depend on accurate patient imaging, anatomical modeling, treatment-machine data, and appropriate commissioning and quality assurance.
- MRI images may be used for treatment planning when appropriately registered with planning CT or other required imaging; MRI safety applies to the scanner and accessories, not to Eclipse software itself.
- The system is not a substitute for clinical judgment, treatment verification, or required radiation safety and quality-control procedures.
Frequently Asked Questions
What are the clinical indications for Eclipse treatment planning system?
The Eclipse system is indicated for use in radiotherapy treatment planning, particularly for calculating and optimizing radiation doses for cancer patients.
What outcomes have been reported in clinical studies?
Studies have reported accurate dose calculations and effective management of dosimetric parameters, especially in photon and electron therapies.
What complications have been reported?
Safety data indicate potential dose inaccuracies near metal elements due to CT artefacts, highlighting the importance of accurate input data and algorithm selection.